Biotech Hangout

→ WHAT IT COVERS Biotech Hangout Episode 180 covers the XBI reaching post-pandemic highs, Kilera's $625M IPO, Revolution Medicines' pancreatic cancer data showing a 0.4 overall survival hazard ratio, Allogene's allogeneic CAR-T results, Spire's UC data, and the FDA's approval of sparsentan for FSGS despite a failed eGFR endpoint. → KEY INSIGHTS - **XBI Construction Shift:** The XBI's methodology has moved away from equal-weight across broad stocks toward weighting larger, more liquid companies.

→ WHAT IT COVERS Biotech Hangout Episode 179 covers biotech market performance with XBI up 84% year-over-year, Merck's $6.7B Terns acquisition backstory, Gilead's $3.15B Tubulus ADC platform deal, Neurocrine's $3B Soleno purchase, FDA regulatory developments, and new obesity drug approvals from Novo Nordisk and Eli Lilly. → KEY INSIGHTS - **Biotech Market Outperformance:** The XBI ETF hit a 52-week high near 132, delivering an 84% return over the past year versus 30% for the S&P 500 and 39% for...

→ WHAT IT COVERS Biotech Hangout Episode 178 covers Q1 2026 biotech market performance, three major M&A deals (Biogen/Apellis at $5.6B, Eli Lilly/Centessa at $6B, Cyclerion/Corsana reverse merger), FDA regulatory shifts favoring orphan drugs, Lilly's oral GLP-1 approval, blood-brain barrier shuttle technology momentum, and competitive dynamics in obesity, narcolepsy, and sickle cell disease markets. → KEY INSIGHTS - **Biotech Sector Outperformance:** XBI is up 7.

→ WHAT IT COVERS Biotech Hangout Episode 177 covers the week of March 27, 2026, examining roughly $10 billion in M&A activity including Gilead's $2.2 billion Ouro acquisition and Merck's $6 billion Tern deal, alongside FDA regulatory shifts post-Vinay Prasad, and clinical data from Beam, Sarepta, and Maze Therapeutics. → KEY INSIGHTS - **Biotech relative performance:** XBI is up approximately 2% year-to-date while the S&P 500 is down 6%, an 8-percentage-point spread in three months.

→ WHAT IT COVERS Biotech Hangout Episode 176 covers macroeconomic risks from Middle East conflict driving oil toward $100/barrel, Vinay Prasad's FDA departure, Servier's $2.5B Day One acquisition, phase three data from Roche and Xenon, IDEA Biosciences' upcoming uveal melanoma readout, and competitive dynamics in NMIBC, IgAN, and obesity markets. → KEY INSIGHTS - **Biotech macro resilience:** Rising oil prices near $100/barrel and potential inflation-driven rate increases pose sector risk, but...

→ WHAT IT COVERS Biotech Hangout Episode 175 covers Q1 2026 biotech capital markets recovery, the $2.25B Roivant-Moderna lipid nanoparticle patent settlement, FDA controversy surrounding UniCure's filing rejection, GLP-1 obesity drug market expansion projections, and the growing concentration of biotech investment conferences in Miami each March. → KEY INSIGHTS - **Biotech IPO Recovery:** Q1 2026 is on pace to reach $2.

→ WHAT IT COVERS Biotech Hangout Episode 174 examines the widening gap between FDA rhetoric on rare disease flexibility and actual agency decisions, covering Atara/Pierre Fabre's double CRL, Gilead's Arcellix acquisition, Novo Nordisk's cagrilintide failure against tirzepatide, and Xenon's upcoming phase three epilepsy readout with Adam Feuerstein. → KEY INSIGHTS - **FDA Leadership Disconnect:** When a new agency head like Vinay Prasad takes over CBER, prior agreements with review teams carry...

→ WHAT IT COVERS Biotech Hangout Episode 173 covers China's record-breaking out-licensing deal surge, FDA instability under Marty Makary and Vinay Prasad including the Moderna vaccine reversal, XBI market sentiment, Keytruda patent protection extending to 2033, and positive phase three data from Compass Pathways in treatment-resistant depression. → KEY INSIGHTS - **China out-licensing acceleration:** China out-licensing deals hit $137.

→ WHAT IT COVERS Biotech Hangout Episode 172 examines the robust IPO market with four deals pricing in one week including ICON's $400M raise, Medicare drug price negotiations impacting innovation, obesity market dynamics following Novo Nordisk's weak guidance versus Eli Lilly's $80-83B forecast, and FDA intervention against compounding pharmacies mass-marketing copycat GLP-1 drugs.

→ WHAT IT COVERS BIO CEO John Crowley discusses US-China biotech competition, FDA modernization challenges, vaccine hesitancy, and policy threats including MFN drug pricing and tariffs. The conversation covers regulatory reform needs, clinical trial cost reduction strategies, and industry efforts to maintain American innovation leadership while addressing access barriers and insurance reform priorities.

→ WHAT IT COVERS Biotech leaders analyze sector optimism following XBI's 30% rise, examining pharmaceutical M&A dynamics with a $90 billion revenue gap requiring deals at 6.5x forward revenue multiples. Discussion covers GSK's $2.2 billion Rapt acquisition, FDA policy shifts under Vinay Prasad, women's health investment momentum, and atopic dermatitis market expansion with novel ITK inhibitors.

→ WHAT IT COVERS JPMorgan Healthcare Conference 2026 signals positive biotech sentiment with seven-out-of-ten optimism. Limited M&A activity reflects stronger company positions and cash reserves. Key developments include Moderna's improved guidance, obesity drug competition intensifying, FDA flexibility debates continuing, and Lilly's Alzheimer's prevention trial TB3 expected in 2027 generating significant interest across neurodegenerative disease space.

→ WHAT IT COVERS Biotech Hangout opens 2026 with analysis of strong sector momentum driven by M&A activity, successful IPOs, and positive market sentiment. The XBI trades at 2125, matching November 2021 levels. Discussion covers Revolution Medicine takeover rumors, Actis Pharmaceuticals IPO raising $318 million, emerging obesity mechanisms beyond GLP-1s, and policy concerns including CDC vaccine schedule changes and CMS pricing demonstrations.

→ WHAT IT COVERS Biotech Hangout's 2025 year-end review examines market recovery after years of underperformance, with XBI reaching 124. Discussion covers FDA staffing crisis with 4,000 employees lost, MFN pricing policy concerns, follow-on financing trends exceeding $9 billion in October-November, and predictions for 2026 IPO activity and continued M&A momentum.

→ WHAT IT COVERS Biotech Hangout Episode 166 examines the 2026 National Defense Authorization Act's biotech provisions, BioSecure Act implications, ASH conference data on CAR-T therapies and bispecifics in multiple myeloma, ESMO Asia oncology updates, Dyne's positive DMD exon skipper data, obesity pipeline developments, and industry sentiment heading into 2026 with optimism scores averaging 7.5-8 out of 10.

→ WHAT IT COVERS Biotech analysts examine 2026 sector outlook following strong 2025 rally, discussing FDA leadership changes under Rick Pazdur's resignation, regulatory uncertainty for rare disease therapies like UniQure's Huntington's treatment, IPO market predictions ranging from 15 to 50 companies, vaccine policy controversies, and competitive dynamics affecting data disclosure practices in oncology development.

→ WHAT IT COVERS Biotech insiders analyze the heated M&A environment with competitive bidding wars for Avadel and record-breaking acquisitions including J&J's $3 billion Halda deal and Merck's Sadara purchase. Discussion covers FDA functionality concerns, vaccine policy changes at CDC, drug pricing strategies from Arrowhead and Novo Nordisk, and emerging royalty-based business models in biotech. → KEY INSIGHTS - **Competitive M&A Dynamics:** Alkermes secured Avadel for $22.

→ WHAT IT COVERS Biotech industry leaders analyze FDA leadership changes with Rick Pazdur's CDER appointment, debate the new plausible mechanism pathway for rare disease therapies, examine major M&A activity including Pfizer-MedSera and Merck-Cidara deals totaling over $20 billion, and review clinical data from Alkermes' narcolepsy program and CRISPR's ANGPTL3 gene editing trial.